Filing Details
- Accession Number:
- 0001415889-23-014758
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-03 16:30:11
- Reporting Period:
- 2023-11-02
- Accepted Time:
- 2023-11-03 16:30:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1082554 | United Therapeutics Corp | UTHR | Pharmaceutical Preparations (2834) | 521984749 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1231589 | A Paul Mahon | C/O United Therapeutics Corporation 1000 Spring Street Silver Spring MD 20910 | Evp & General Counsel | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-11-02 | 6,000 | $117.76 | 42,599 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-11-02 | 400 | $222.85 | 42,199 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-11-02 | 1,300 | $224.36 | 40,899 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-11-02 | 600 | $225.24 | 40,299 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-11-02 | 3,100 | $226.52 | 37,199 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-11-02 | 600 | $227.30 | 36,599 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options | Disposition | 2023-11-02 | 6,000 | $0.00 | 600 | $117.76 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 108,000 | 2021-03-15 | 2027-03-15 | No | 4 | M | Direct |
Footnotes
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023.
- This transaction was executed in multiple trades at prices ranging from $222.445 to $223.035. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $223.90 to $224.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $225.02 to $225.815. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $226.05 to $226.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $227.08 to $227.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Billionaire Hedge Funds
